A new study has found that the type 2 diabetes treatment rosiglitazone increased high-density lipoprotein (HDL, or "good") cholesterol levels and improved the ratio of total cholesterol to HDL cholesterol in patients with type 2 diabetes. Data from the study were presented recently at the Annual Scientific Session of the American College of Cardiology.
In the study?which analyzed the results of open-label extensions of 2 placebo-controlled, double-blind studies?a total of 269 patients were given 8 mg of rosiglitazone daily for 24 months. In all the patients, mean HDL cholesterol levels increased by 15%, with increases of 25% in patients with HDL cholesterol levels <40 mg/dL at baseline.The ratio of cholesterol to HDL cholesterol improved for all the patients, with an overall decrease from 5.06 to 4.7 over 2 years. In patients with a ratio >5, the mean ratio decreased from 6.25 to 5.6.
One study linked multiple pregnancies to an increased risk of developing atrial fibrillation later in life, and another investigated the association between premature delivery and cardiovascular disease.
Clinical features with downloadable PDFs